USSTOCK.TODAY
After-Market
Log in Sign up

Genmab shares surge 13% following announcement of colorectal cancer treatment clinical results

Investing.com · ·by G4L

GMAB Genmab ADR
$54.07 -3.10%
View chart & analysis →
  1. 1Genmab shares rose 13% on Monday.
  2. 2A 75% tumor reduction rate was observed in untreated patients with advanced colorectal cancer during the mid-term clinical trial.
  3. 3Chief Medical Officer Tahman Ahmadi stated that the results provide strong evidence for the company's ongoing Phase 3 clinical trial.

So what's the key point?

Genmab announced that its colorectal cancer treatment trial reduced tumors by 75%. The stock price rose because these results provide a basis for the next stage of ongoing trials.

Source Investing.com · View original ↗

Related 3-line summaries

Genmab reports 22% increase in total revenue for first nine months of 2026 The Motley Fool +1 · 4d agoZenmap confirms 50% reduction in death risk in first-line head and neck squamous cell carcinoma clinical trial Clinical Trials Arena · Oct 30Genmab shares rise 9% on positive Phase 3 clinical trial results for ovarian cancer treatment Investing.com +1 · Oct 24
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news